Citryll strengthens IP portfolio with grant of EC of matter patent for CIT-013 to treat extracellular trap-driven pathologies: Oss, Netherlands Friday, April 17, 2026, 16:00 Hrs [ ...
April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), today announces that the European ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する